Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) FCF Margin (2022 - 2025)

Historic FCF Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 127.77%.

  • ARS Pharmaceuticals' FCF Margin rose 5785700.0% to 127.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 60.25%, marking a year-over-year increase of 17322400.0%. This contributed to the annual value of 14.57% for FY2024, which is 1981512300.0% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' FCF Margin is 127.77%, which was up 5785700.0% from 288.61% recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year FCF Margin high stood at 48.17% for Q4 2024, and its period low was 166990.0% during Q2 2023.
  • Over the past 4 years, ARS Pharmaceuticals' median FCF Margin value was 1047.66% (recorded in 2022), while the average stood at 21702.52%.
  • In the last 5 years, ARS Pharmaceuticals' FCF Margin plummeted by -1654822400bps in 2023 and then surged by 1655266000bps in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' FCF Margin stood at 3022.22% in 2022, then tumbled by -5425bps to 166990.0% in 2023, then soared by 100bps to 48.17% in 2024, then tumbled by -365bps to 127.77% in 2025.
  • Its last three reported values are 127.77% in Q3 2025, 288.61% for Q2 2025, and 512.14% during Q1 2025.